BACE1 inhibitors: Attractive therapeutics for alzheimer's disease

Boris DeCourt, Mi Mi Macias, Marwan Sabbagh, Abdu Adem

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

One of the neuropathological hallmarks of Alzheimer's disease (AD) is the presence of brain senile plaques made up principally of aggregated amyloid beta (Aβ) peptides. Aβ is produced during the consecutive proteolysis of the transmembrane amyloid precursor protein (APP) by β- and γ-secretases. Genetic and pharmacological manipulations have demonstrated the major β -secretase in AD that makes the initial cleavage required for synthesis of Aβ is the beta-site APP-cleaving enzyme 1 (BACE1). It is therefore very tempting to consider inhibiting BACE1 as a potential AD therapeutic intervention. Here, we review the current knowledge and the molecular and physiological challenges associated with BACE1 inhibition. We also propose alternatives to the direct targeting of CNS BACE1 to prevent AD, as well as methods to measure the therapeutic efficacy of BACE1 inhibition.

Original languageEnglish (US)
Title of host publicationDrug Design and Discovery in Alzheimer's Disease
PublisherElsevier Inc.
Pages518-546
Number of pages29
ISBN (Electronic)9780128039595
ISBN (Print)9780128039595
DOIs
StatePublished - Jun 2 2015
Externally publishedYes

Fingerprint

Enzymes
Amyloid Precursor Protein Secretases
Proteolysis
Amyloid beta-Protein Precursor
Amyloid
Brain
Peptides

Keywords

  • Alzheimer's
  • Amyloid
  • APP
  • BACE1
  • Bapineuzumab
  • Beta-secretase
  • Blood brain barrier
  • Central nervous system
  • Clinical trial
  • Design
  • Down syndrome
  • Gamma-secretase
  • Immunotherapy
  • Inhibition
  • Modulation
  • Optimization
  • Peptidomimetic
  • Periphery
  • Solanezumab
  • Trafficking

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

DeCourt, B., Macias, M. M., Sabbagh, M., & Adem, A. (2015). BACE1 inhibitors: Attractive therapeutics for alzheimer's disease. In Drug Design and Discovery in Alzheimer's Disease (pp. 518-546). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-803959-5.50010-6

BACE1 inhibitors : Attractive therapeutics for alzheimer's disease. / DeCourt, Boris; Macias, Mi Mi; Sabbagh, Marwan; Adem, Abdu.

Drug Design and Discovery in Alzheimer's Disease. Elsevier Inc., 2015. p. 518-546.

Research output: Chapter in Book/Report/Conference proceedingChapter

DeCourt, B, Macias, MM, Sabbagh, M & Adem, A 2015, BACE1 inhibitors: Attractive therapeutics for alzheimer's disease. in Drug Design and Discovery in Alzheimer's Disease. Elsevier Inc., pp. 518-546. https://doi.org/10.1016/B978-0-12-803959-5.50010-6
DeCourt B, Macias MM, Sabbagh M, Adem A. BACE1 inhibitors: Attractive therapeutics for alzheimer's disease. In Drug Design and Discovery in Alzheimer's Disease. Elsevier Inc. 2015. p. 518-546 https://doi.org/10.1016/B978-0-12-803959-5.50010-6
DeCourt, Boris ; Macias, Mi Mi ; Sabbagh, Marwan ; Adem, Abdu. / BACE1 inhibitors : Attractive therapeutics for alzheimer's disease. Drug Design and Discovery in Alzheimer's Disease. Elsevier Inc., 2015. pp. 518-546
@inbook{e351f6eed11545b384736a14c7a1272e,
title = "BACE1 inhibitors: Attractive therapeutics for alzheimer's disease",
abstract = "One of the neuropathological hallmarks of Alzheimer's disease (AD) is the presence of brain senile plaques made up principally of aggregated amyloid beta (Aβ) peptides. Aβ is produced during the consecutive proteolysis of the transmembrane amyloid precursor protein (APP) by β- and γ-secretases. Genetic and pharmacological manipulations have demonstrated the major β -secretase in AD that makes the initial cleavage required for synthesis of Aβ is the beta-site APP-cleaving enzyme 1 (BACE1). It is therefore very tempting to consider inhibiting BACE1 as a potential AD therapeutic intervention. Here, we review the current knowledge and the molecular and physiological challenges associated with BACE1 inhibition. We also propose alternatives to the direct targeting of CNS BACE1 to prevent AD, as well as methods to measure the therapeutic efficacy of BACE1 inhibition.",
keywords = "Alzheimer's, Amyloid, APP, BACE1, Bapineuzumab, Beta-secretase, Blood brain barrier, Central nervous system, Clinical trial, Design, Down syndrome, Gamma-secretase, Immunotherapy, Inhibition, Modulation, Optimization, Peptidomimetic, Periphery, Solanezumab, Trafficking",
author = "Boris DeCourt and Macias, {Mi Mi} and Marwan Sabbagh and Abdu Adem",
year = "2015",
month = "6",
day = "2",
doi = "10.1016/B978-0-12-803959-5.50010-6",
language = "English (US)",
isbn = "9780128039595",
pages = "518--546",
booktitle = "Drug Design and Discovery in Alzheimer's Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - BACE1 inhibitors

T2 - Attractive therapeutics for alzheimer's disease

AU - DeCourt, Boris

AU - Macias, Mi Mi

AU - Sabbagh, Marwan

AU - Adem, Abdu

PY - 2015/6/2

Y1 - 2015/6/2

N2 - One of the neuropathological hallmarks of Alzheimer's disease (AD) is the presence of brain senile plaques made up principally of aggregated amyloid beta (Aβ) peptides. Aβ is produced during the consecutive proteolysis of the transmembrane amyloid precursor protein (APP) by β- and γ-secretases. Genetic and pharmacological manipulations have demonstrated the major β -secretase in AD that makes the initial cleavage required for synthesis of Aβ is the beta-site APP-cleaving enzyme 1 (BACE1). It is therefore very tempting to consider inhibiting BACE1 as a potential AD therapeutic intervention. Here, we review the current knowledge and the molecular and physiological challenges associated with BACE1 inhibition. We also propose alternatives to the direct targeting of CNS BACE1 to prevent AD, as well as methods to measure the therapeutic efficacy of BACE1 inhibition.

AB - One of the neuropathological hallmarks of Alzheimer's disease (AD) is the presence of brain senile plaques made up principally of aggregated amyloid beta (Aβ) peptides. Aβ is produced during the consecutive proteolysis of the transmembrane amyloid precursor protein (APP) by β- and γ-secretases. Genetic and pharmacological manipulations have demonstrated the major β -secretase in AD that makes the initial cleavage required for synthesis of Aβ is the beta-site APP-cleaving enzyme 1 (BACE1). It is therefore very tempting to consider inhibiting BACE1 as a potential AD therapeutic intervention. Here, we review the current knowledge and the molecular and physiological challenges associated with BACE1 inhibition. We also propose alternatives to the direct targeting of CNS BACE1 to prevent AD, as well as methods to measure the therapeutic efficacy of BACE1 inhibition.

KW - Alzheimer's

KW - Amyloid

KW - APP

KW - BACE1

KW - Bapineuzumab

KW - Beta-secretase

KW - Blood brain barrier

KW - Central nervous system

KW - Clinical trial

KW - Design

KW - Down syndrome

KW - Gamma-secretase

KW - Immunotherapy

KW - Inhibition

KW - Modulation

KW - Optimization

KW - Peptidomimetic

KW - Periphery

KW - Solanezumab

KW - Trafficking

UR - http://www.scopus.com/inward/record.url?scp=84940835255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940835255&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-803959-5.50010-6

DO - 10.1016/B978-0-12-803959-5.50010-6

M3 - Chapter

AN - SCOPUS:84940835255

SN - 9780128039595

SP - 518

EP - 546

BT - Drug Design and Discovery in Alzheimer's Disease

PB - Elsevier Inc.

ER -